AIMC Topic: Infliximab

Clear Filters Showing 1 to 10 of 16 articles

Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn's disease.

Annals of medicine Jul 5, 2025
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory bowel disease, with infliximab (IFX) commonly used for treatment. However, no clinically applicable model currently exists to predict the response of patients with CD to IFX therapy. Given th...
Tomography, X-Ray Computed Female Adult Radiomics Humans Machine Learning Retrospective Studies Sarcopenia Infliximab Crohn Disease Gastrointestinal Agents Psoas Muscles Male Middle Aged ROC Curve Treatment Outcome
View on PubMed DOI

Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.

Journal of pediatric gastroenterology and nutrition Dec 27, 2023
BACKGROUND: Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.
Drug Monitoring Immunologic Factors Antibodies Infliximab Gastrointestinal Agents Humans Young Adult Crohn Disease Prospective Studies Adolescent Inflammatory Bowel Diseases Child Female Colitis, Ulcerative
View on PubMed DOI

Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease.

Journal of pediatric gastroenterology and nutrition Dec 10, 2023
OBJECTIVES: While higher infliximab (IFX) trough concentrations (TCs) are associated with better outcomes in patients with inflammatory bowel disease (IBD), they could pose a risk for adverse events (AEs), including IFX-induced skin lesions. Therefor...
Remission Induction Skin Diseases Humans Inflammatory Bowel Diseases Infliximab Female Crohn Disease Risk Factors Gastrointestinal Agents Child Tumor Necrosis Factor Inhibitors Colitis, Ulcerative
View on PubMed DOI

Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.

Journal of pediatric gastroenterology and nutrition Dec 5, 2023
OBJECTIVES: Antibodies to infliximab (ATIs) are associated with loss of response in children with inflammatory bowel disease (IBD). We aimed to describe the effectiveness of strategies for treatment modification following ATI development in pediatric...
Gastrointestinal Agents Tumor Necrosis Factor Inhibitors Retrospective Studies Humans Child Inflammatory Bowel Diseases Antibodies Infliximab
View on PubMed DOI

Aggregate Formation and Antibody Stability in Infusion Bags: The Impact of Manual and Robotic Compounding of Monoclonal Antibodies.

Journal of pharmaceutical sciences Oct 13, 2023
Monoclonal antibodies (mAbs) can be damaged during the aseptic compounding process, with aggregation being the most prevalent form of degradation. Protein aggregates represent one of several risk factors for undesired immunogenicity of mAbs, which ca...
Trastuzumab Humans Antibodies, Monoclonal Robotics Robotic Surgical Procedures Infliximab Drug Compounding
View on PubMed DOI

Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis.

Frontiers in immunology Dec 21, 2021
Infliximab (IFX) is an effective medication for ulcerative colitis (UC) patients. However, one-third of UC patients show primary non-response (PNR) to IFX. Our study analyzed three Gene Expression Omnibus (GEO) datasets and used the RobustRankAggreg ...
Infliximab Gastrointestinal Agents Humans Neural Networks, Computer Colitis, Ulcerative
View on PubMed DOI

Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction.

Frontiers in immunology Jun 23, 2020
Recombinant DNA technology has, in the last decades, contributed to a vast expansion of the use of protein drugs as pharmaceutical agents. However, such biological drugs can lead to the formation of anti-drug antibodies (ADAs) that may result in adve...
Dendritic Cells Protein Binding Proteomics Mass Spectrometry Humans Neural Networks, Computer Epitopes, T-Lymphocyte Peptides Histocompatibility Antigens Class II CD4-Positive T-Lymphocytes Infliximab Antirheumatic Agents Rituximab
View on PubMed DOI

Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.

Arthritis & rheumatology (Hoboken, N.J.) Nov 4, 2019
OBJECTIVE: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti-tumor necrosis factor (anti-TNF) drugs are an important second-line treatment after methotr...
Antirheumatic Agents Normal Distribution Etanercept Certolizumab Pegol Genetic Markers Methotrexate Adalimumab Outcome Assessment, Health Care Middle Aged Severity of Illness Index Arthritis, Rheumatoid Polymorphism, Single Nucleotide Treatment Outcome Regression Analysis Predictive Value of Tests Infliximab Tumor Necrosis Factor-alpha Female Reproducibility of Results Humans Male Machine Learning
View on PubMed DOI

Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series.

Cytokine Dec 29, 2017
Up to 50% of patients with ulcerative colitis (UC) or Crohn's disease (CD) experience a loss of response (LOR) to infliximab after an initial response to the drug. Granulocyte/monocyte apheresis (GMA) with the Adacolumn depletes the activated myeloid...
Middle Aged Time Factors Interleukin-17 Colitis, Ulcerative C-Reactive Protein Infliximab Leukapheresis Prospective Studies Female Adult Male Humans Interleukin-6
View on PubMed DOI

Stability of infliximab solutions in different temperature and dilution conditions.

Journal of pharmaceutical and biomedical analysis Dec 18, 2017
Infliximab is a monoclonal antibody widely used for the treatment of inflammatory diseases. Over the past few years, many studies have assessed that monoclonal antibodies are prone to aggregation under stress conditions. The aim of this study was to ...
Nephelometry and Turbidimetry Peptide Mapping Temperature Osmolar Concentration Pharmaceutical Solutions Technology, Pharmaceutical Antirheumatic Agents Biosimilar Pharmaceuticals Protein Aggregates Protein Stability Time Factors Spectrophotometry, Ultraviolet Drug Stability Nanoparticles Chromatography, Gel Drug Compounding Spectroscopy, Fourier Transform Infrared Chromatography, Ion Exchange Infliximab
View on PubMed DOI
Popular Topics
Recent Journals